Literature DB >> 34421423

There is an Association of Synovial Interleukin-6 Levels With Chondral Damage in Anterior Cruciate Ligament-Deficient Knees.

Ravi Gupta1, Anil Kapoor1, Sourabh Khatri2, Dinesh Sandal1, Gladson David Masih1.   

Abstract

Background: Osteoarthritis (OA) in the anterior cruciate ligament (ACL)-deficient knee is seen in approximately 50% of affected patients. Possible causes include biochemical or biomechanical changes. Purpose: We sought to study the correlation between inflammatory cytokines and chondral damage in ACL-deficient knees.
Methods: Seventy-six male patients who underwent ACL reconstruction were enrolled in a cross-sectional study. Synovial fluid was aspirated before surgery and analyzed for levels of the inflammatory cytokines tumor necrosis factor-α, interleukin-1 (IL-1), and interleukin-6 (IL-6). At the time of ACL reconstruction, the severity of chondral damage was documented as described by the Outerbridge classification.
Results: Patients with grade 2 or higher chondral damage were observed to have elevated IL-6 levels when compared to patients who had no chondral damage. Interleukin-6 levels had no correlation with the duration of injury.
Conclusion: Elevated levels of IL-6 in synovial fluid were associated with chondral damage in ACL-deficient knees. Further study is warranted to determine whether inflammatory cytokines contribute to the development of OA of the knee after ACL injury.
© The Author(s) 2021.

Entities:  

Keywords:  ACL; chondral damage; inflammatory cytokines; osteoarthritis

Year:  2021        PMID: 34421423      PMCID: PMC8361593          DOI: 10.1177/1556331621992006

Source DB:  PubMed          Journal:  HSS J        ISSN: 1556-3316


  33 in total

1.  Function, osteoarthritis and activity after ACL-rupture: 11 years follow-up results of conservative versus reconstructive treatment.

Authors:  M A Kessler; H Behrend; S Henz; G Stutz; A Rukavina; M S Kuster
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-05       Impact factor: 4.342

Review 2.  Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation.

Authors:  E Hedbom; H J Häuselmann
Journal:  Cell Mol Life Sci       Date:  2002-01       Impact factor: 9.261

3.  Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis.

Authors:  S Kaneko; T Satoh; J Chiba; C Ju; K Inoue; J Kagawa
Journal:  Cytokines Cell Mol Ther       Date:  2000-06

4.  Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis.

Authors:  P Swärd; R Frobell; M Englund; H Roos; A Struglics
Journal:  Osteoarthritis Cartilage       Date:  2012-08-05       Impact factor: 6.576

5.  Serum estrogen and interleukin-6 levels in postmenopausal female osteoarthritis patients.

Authors:  Sadia Afzal; Aziza Khanam
Journal:  Pak J Pharm Sci       Date:  2011-04       Impact factor: 0.684

6.  Cytokine profiling in acute anterior cruciate ligament injury.

Authors:  Vanessa G Cuellar; Jason M Cuellar; S Raymond Golish; David C Yeomans; Gaetano J Scuderi
Journal:  Arthroscopy       Date:  2010-10       Impact factor: 4.772

Review 7.  Acute-phase proteins in osteoarthritis.

Authors:  J D Sipe
Journal:  Semin Arthritis Rheum       Date:  1995-10       Impact factor: 5.532

8.  Fate of the ACL-injured patient. A prospective outcome study.

Authors:  D M Daniel; M L Stone; B E Dobson; D C Fithian; D J Rossman; K R Kaufman
Journal:  Am J Sports Med       Date:  1994 Sep-Oct       Impact factor: 6.202

9.  CX3CL1 promotes MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-κB signaling pathway in osteoarthritis synovial fibroblasts.

Authors:  Sheng-Mou Hou; Chun-Han Hou; Ju-Fang Liu
Journal:  Arthritis Res Ther       Date:  2017-12-21       Impact factor: 5.156

10.  Molecular changes indicative of cartilage degeneration and osteoarthritis development in patients with anterior cruciate ligament injury.

Authors:  Ioanna Papathanasiou; Sotirios Michalitsis; Michael E Hantes; Marianna Vlychou; Lydia Anastasopoulou; Konstantinos N Malizos; Aspasia Tsezou
Journal:  BMC Musculoskelet Disord       Date:  2016-01-13       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.